Avstera Therapeutics is focused on developing innovative solutions for advanced cancer patients, particularly those with solid tumors who have limited treatment options. Their proprietary pipeline includes AVS100, a highly selective, orally bioavailable HDAC6 inhibitor that has received IND clearance from the FDA for first-in-human trials. AVS100 targets the tumor microenvironment by suppressing the polarization of pro-tumoral macrophages, which are often abundant in solid tumors and contribute to treatment resistance. Preclinical studies have demonstrated its efficacy in reducing tumor growth, both as a monotherapy and in combination with existing therapies like pembrolizumab, while also showing a favorable safety profile.

In addition to AVS100, Avstera is advancing AVS200, a first-in-class myeloid cell therapy platform. This platform aims to leverage the functions of myeloid cells to counteract immunosuppressive pathways within tumors. The company has established proof-of-concept for an autologous macrophage cell therapy that maintains an anti-tumoral M1 phenotype in various models. Avstera is also exploring innovative engineered cell types, including mRNA-CAR-Macrophages and mRNA-CAR-Monocytes, with plans to select a lead candidate for further development. Through these technologies, Avstera aims to address significant unmet needs in cancer treatment and improve outcomes for patients with advanced solid tumors.

United States

Specialty oncology-focused biopharmaceutical company based in Malvern, PA  with a broad pipeline encompassing novel best in class selective HDAC6i immunomodulators and a game changing myeloid based discovery platform.  Avstera focuses on foundational tumor biology science, while methodologically breaking barriers using cutting-edge approaches in order to deliver impactful treatments to cancer patients.  

Avstera Therapeutics

Company Details